NewKerala.com

India's Bioeconomy Nears $200B Mark, Poised for Innovation-Led Growth

India's bioeconomy is approaching $200 billion, having expanded sharply from about $10 billion in 2014 and now contributing nearly 5% to the nation's GDP. The country, known as the 'Pharmacy of the World', is transitioning towards an innovation-led biopharma ecosystem focused on novel therapeutics. This growth is driven by favourable policy measures, regulatory reforms, and key government initiatives like the proposed Biopharma Shakti scheme. Despite challenges in infrastructure and funding, India's ecosystem of over 2,500 startups is well-positioned to become a global hub for cost-efficient biopharma innovation.

Key Points: India's Bioeconomy Hits $200B, Fuels Next Growth Phase

  • Bioeconomy grew from $10B (2014) to $195B (2026)
  • Transitioning to innovation-led biopharma ecosystem
  • Key govt schemes like Biopharma Shakti & RDI Fund
  • Regulatory reforms to cut drug development cycles
2 min read

India's bioeconomy nears $200 billion, innovation push signals next growth phase

India's bioeconomy nears $200 billion, contributing 5% to GDP. Innovation push and policy reforms signal major growth in biopharma.

"With sustained policy support and deeper ecosystem collaboration, India has the potential to emerge as a global hub for cost-efficient, high-quality biopharma innovation. - Endiya Partners report"

New Delhi, March 31

India's bioeconomy is approaching the $200 billion mark, which is a significant milestone in its evolution with a strong policy push and growing innovation pipeline signalling the next phase of growth, according to a report released on Tuesday.

The report by Endiya Partners said that the nation's bioeconomy has expanded sharply from around $10 billion in 2014 to over $195 billion in 2026, now contributing nearly 5 per cent to the GDP.

India, long recognised as the 'Pharmacy of the World' for supplying nearly 20 per cent of global generics and over 60 per cent of vaccines, is now transitioning towards an innovation-led biopharma ecosystem focused on novel therapeutics and deep-tech platforms.

The report highlighted that India stands at an inflection point, driven by favourable policy measures, regulatory reforms, and increasing global validation of its clinical-stage assets.

It also highlighted key government initiatives -- including the proposed Rs 10,000 crore Biopharma Shakti scheme and the Rs 1,00,000 crore Research, Development and Innovation (RDI) Fund -- that are expected to accelerate the development of a robust innovation ecosystem.

Recent regulatory reforms, such as the introduction of a 45-day approval timeline and prior intimation pathways, are also likely to reduce administrative bottlenecks and compress drug development cycles by up to four months, it added.

At the same time, structural shifts in the global biopharma industry, including rising R&D costs, estimated at $2.2 billion per asset, and a looming $300 billion patent cliff, are creating opportunities for cost-efficient and high-velocity research ecosystems like India.

The report also noted that Indian biotech startups benefit from a 'Recruitment Alpha', enabling significantly faster patient enrolment and allowing drug candidates to advance to Phase II trials at substantially lower costs compared to global peers.

This advantage enables Indian firms to take multiple parallel bets in drug development, improving overall success probabilities, it added.

However, the report cautioned that challenges remain, including gaps in pilot-scale GMP infrastructure, limited late-stage funding, talent shortages, and the need for stronger translational research capabilities.

Despite these constraints, India's biopharma ecosystem -- comprising over 2,500 startups, around 100 incubators, and more than 600 research institutes -- is well-positioned to support the next phase of growth.

"With sustained policy support and deeper ecosystem collaboration, India has the potential to emerge as a global hub for cost-efficient, high-quality biopharma innovation," the report said.

- IANS

Share this article:

Reader Comments

P
Priya S
Very promising, but the report itself points out the challenges. Gaps in infrastructure and late-stage funding are serious issues. We need more than just big announcements for the RDI fund; we need transparent and efficient disbursement to actually reach startups.
R
Rohit P
The 'Recruitment Alpha' is our secret weapon! Faster patient enrolment means we can develop drugs cheaper and quicker than the West. This is a massive competitive advantage for Indian biotech. Hope our startups leverage this fully.
S
Sarah B
As someone working in the life sciences sector here, the 45-day approval timeline is a game-changer if implemented properly. The bureaucratic delays were a major pain point. This can really boost investor confidence.
K
Karthik V
Contributing 5% to GDP is no small feat. This sector can create so many high-quality jobs for our science and engineering graduates. The focus must be on bridging that talent shortage mentioned. We need more specialized courses in biotech and pharma management.
M
Michael C
The global patent cliff creating a $300B opportunity is the key point. Indian companies have the generics expertise and now, with this innovation push, they are perfectly positioned to capture a significant share. Strategic timing.

We welcome thoughtful discussions from our readers. Please keep comments respectful and on-topic.

Leave a Comment

Minimum 50 characters 0/50